Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, ...
Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...
Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...
Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.
Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.